MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414605 | Name: Treprostinil diolamine
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Treprostinil is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a chemically stable prostacyclin analog. Its principal pharmacologic action is direct vasodilation, which causes reduction of pulmonary and systemic arterial pressure, reducing right and left ventricular afterload; therefore improves the cardiac output. It also has an antiplatelet effect.

Chemical Structure

Treprostinil diolamine
Treprostinil diolamine
CAS#830354-48-8 (diolamine)

Theoretical Analysis

MedKoo Cat#: 414605

Name: Treprostinil diolamine

CAS#: 830354-48-8 (diolamine)

Chemical Formula: C27H45NO7

Exact Mass: 0.0000

Molecular Weight: 495.66

Elemental Analysis: C, 65.43; H, 9.15; N, 2.83; O, 22.59

Price and Availability

Size Price Availability Quantity
50mg USD 750.00 2 Weeks
100mg USD 1,350.00 2 Weeks
200mg USD 2,350.00 2 Weeks
500mg USD 3,850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
289480-64-4 (sodium) 81846-19-7 (free acid) 830354-48-8 (diolamine)
Synonym
Treprostinil diolamine; UT-15C; UT15C; UT 15C
IUPAC/Chemical Name
2-((1R,2R,3aS,9aS)-2-Hydroxy-1-(3(S)-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta(b)naphthalen-5-yloxy)acetic acid diethanolamine salt
InChi Key
RHWRWEUCEXUUAV-ZSESPEEFSA-N
InChi Code
InChI=1S/C23H34O5.C4H11NO2/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25;6-3-1-5-2-4-7/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27);5-7H,1-4H2/t16-,17-,18+,19-,21+;/m0./s1
SMILES Code
OCC[NH2+]CCO.O=C([O-])COC1=CC=CC2=C1C[C@]3([H])[C@]([C@@H](CC[C@@H](O)CCCCC)[C@H](O)C3)([H])C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 495.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Pradhan A, Tyagi R, Sharma P, Bajpai J, Kant S. Shifting Paradigms in the Management of Pulmonary Hypertension. Eur Cardiol. 2024 Dec 23;19:e25. doi: 10.15420/ecr.2024.11. PMID: 39872419; PMCID: PMC11770536. 2: Kędzierski P, Banaszkiewicz M, Florczyk M, Piłka M, Mańczak R, Wieteska-Miłek M, Szwed P, Kasperowicz K, Wrona K, Darocha S, Torbicki A, Kurzyna M. The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil. Biomedicines. 2025 Jan 13;13(1):172. doi: 10.3390/biomedicines13010172. PMID: 39857754; PMCID: PMC11760442. 3: Prchal-Murphy M, Zehenter J, Fischer M, Pirabe A, Themanns M, Afrashteh B, Putz EM, Kollmann K, Basílio J, Salzmann M, Strohmaier W, Krumpl G, Farr A, Sexl V, Freissmuth M, Zebedin-Brandl E. Repurposing the prostaglandin analogue treprostinil and the calcium-sensing receptor modulator cinacalcet to revive cord blood as an alternate source of hematopoietic stem and progenitor cells for transplantation. Front Pharmacol. 2025 Jan 9;15:1444311. doi: 10.3389/fphar.2024.1444311. PMID: 39850556; PMCID: PMC11755040. 4: Stine AE, Parmar J, Smith AK, Cummins Z, Pillalamarri NR, Bender RJ. Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population. NPJ Syst Biol Appl. 2025 Jan 15;11(1):9. doi: 10.1038/s41540-024-00481-y. PMID: 39814773; PMCID: PMC11735615. 5: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Treprostinil. 2025 Jan 15. PMID: 30000980. 6: Nathan SD, Stinchon MR Jr, Atcheson S, Simone L, Nelson M. Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment. J Manag Care Spec Pharm. 2025 Jan;31(1-a Suppl):S2-S17. doi: 10.18553/jmcp.2025.31.1-a.s2. PMID: 39745852; PMCID: PMC11695281. 7: Heine A, Obst A, Opitz CF, Halank M, Richter M, Lange T, Ewert R. Kombinationstherapie bei pulmonaler arterieller Hypertonie – Switch von Selexipag zu intravenösem Treprostinil [Combination drug therapy in pulmonary hypertension: switch from selexipaq to intravenous trepostinil]. Pneumologie. 2024 Dec 4. German. doi: 10.1055/a-2472-0694. Epub ahead of print. PMID: 39631731. 8: Tang F, Ma Q, Liu Y, Yang X. Risk of respiratory, thoracic, and mediastinal disorders associated with endothelin receptor antagonists and prostacyclin- related drugs in pulmonary hypertension: a disproportionality analysis based on FAERS. Expert Opin Drug Saf. 2024 Dec 3:1-12. doi: 10.1080/14740338.2024.2436077. Epub ahead of print. PMID: 39625736. 9: Harder EM, Rahaghi FN, Leopold JA, Systrom DM, Washko GR, Waxman AB. Vasoreactivity and inhaled treprostinil response in interstitial lung disease pulmonary hypertension. ERJ Open Res. 2024 Dec 2;10(6):00201-2024. doi: 10.1183/23120541.00201-2024. PMID: 39624389; PMCID: PMC11609945. 10: White RJ, El-Kersh K, Rosenkranz S, Franco V, Vizza CD, Badagliacca R, Pepke-Zaba J, Elwing J, Argula RG, Shapiro S, Kim H, Seaman S, Shen E, Das M, Broderick M, McLaughlin V. Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities. Chest. 2024 Nov 30:S0012-3692(24)05604-6. doi: 10.1016/j.chest.2024.11.027. Epub ahead of print. PMID: 39622469. 11: Lee D. Treprostinil Use in the NICU. Adv Neonatal Care. 2024 Dec 1;24(6):554-560. doi: 10.1097/ANC.0000000000001218. Epub 2024 Nov 26. PMID: 39602092. 12: Li L. A Disproportionality Analysis of Treprostinil Based on FDA Adverse Event Reporting System Database. Ann Pharmacother. 2024 Nov 26:10600280241299114. doi: 10.1177/10600280241299114. Epub ahead of print. PMID: 39600147. 13: Perisetla N, Miranda C, Louis J, Omoike O, Farrat N, Camporesi E. Inhaled epoprostenol via high-flow nasal cannula and intravenous treprostinil for management of severe pulmonary arterial hypertension during cesarean delivery with epidural anesthesia: a case report. Int J Obstet Anesth. 2024 Nov 12;61:104295. doi: 10.1016/j.ijoa.2024.104295. Epub ahead of print. PMID: 39580973. 14: Nazabal A, Mendiguren A, Pineda J. Pharmacological characterization of prostaglandin E2 EP2 and EP4 receptors in male rat locus coeruleus neurons ex vivo. Biochem Pharmacol. 2024 Dec;230(Pt 3):116602. doi: 10.1016/j.bcp.2024.116602. Epub 2024 Nov 5. PMID: 39510196. 15: Xiao L, Feng X, Zhang H, Zhong L, Song X, Wang F. Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis. Postepy Kardiol Interwencyjnej. 2024 Sep;20(3):258-263. doi: 10.5114/aic.2024.143558. Epub 2024 Sep 27. PMID: 39464579; PMCID: PMC11506401. 16: Raina A, Sketch MR, Wu B, Broderick M, Shlobin OA. Congruency between clinician-assessed risk and calculated risk of 1-year mortality in patients with pulmonary arterial hypertension: A retrospective chart review. Pulm Circ. 2024 Oct 18;14(4):e12455. doi: 10.1002/pul2.12455. PMID: 39431235; PMCID: PMC11487335. 17: Balakrishnan B, Azar J, Farha S, Goyanes AM, Lane JE, Paul D, Highland KB, Wang Y, Wang X, Tonelli AR. Efficacy and determinants of response to inhaled treprostinil in pulmonary hypertension - interstitial lung disease. Respir Med. 2024 Nov-Dec;234:107835. doi: 10.1016/j.rmed.2024.107835. Epub 2024 Oct 18. PMID: 39426436. 18: Stone JN, Kuebel DJ, Guido MR, Elwing JM, Jose A. Dual prostacyclin infusions: A case report of a patient symptom-driven transition from high-dose intravenous epoprostenol to subcutaneous treprostinil for the treatment of pulmonary arterial hypertension. Am J Health Syst Pharm. 2024 Oct 19:zxae290. doi: 10.1093/ajhp/zxae290. Epub ahead of print. PMID: 39425969. 19: Correction: Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study. BMJ Open Respir Res. 2024 Oct 16;11(1):e002116corr1. doi: 10.1136/bmjresp-2023-002116corr1. Erratum for: BMJ Open Respir Res. 2024 Mar 22;11(1):e002116. doi: 10.1136/bmjresp-2023-002116. PMID: 39414328; PMCID: PMC11487910. 20: Ismail NR, Makhlouf HA, Hassan A, Elshahat A, Abdellatif MA, Rezk AE, Mady A, Mohamed RG, Elfeky HM, Abdelaziz A. An in-depth evaluation of the efficacy and safety of various treatment modalities for chronic thromboembolic pulmonary hypertension: A systematic review and network meta-analysis. Am Heart J Plus. 2024 Sep 24;46:100466. doi: 10.1016/j.ahjo.2024.100466. PMID: 39399578; PMCID: PMC11470563.